➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
McKinsey
Colorcon
Harvard Business School

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 9,809,588

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,809,588
Title:GLS1 inhibitors for treating disease
Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: ##STR00001## Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Inventor(s): Di Francesco; Maria Emilia (Houston, TX), Jones; Philip (Houston, TX), Heffernan; Timothy (Sugar Land, TX), Hamilton; Matthew M. (Missouri City, TX), Kang; Zhijun (Sugar Land, TX), Soth; Michael J. (Sugar Land, TX), Burke; Jason P. (Houston, TX), Le; Kang (Sugar Land, TX), Carroll; Christopher Lawrence (Houston, TX), Palmer; Wylie S. (Houston, TX), Lewis; Richard (Houston, TX), McAfoos; Timothy (Houston, TX), Czako; Barbara (Houston, TX), Liu; Gang (Sugar Land, TX), Theroff; Jay (Manvel, TX), Herrera; Zachary (Houston, TX), Yau; Anne (Houston, TX)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Application Number:14/791,186
Patent Claims:see list of patent claims

Details for Patent 9,809,588

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2034-07-03
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Free Forever Trial 2034-07-03
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 2000-06-28 ⤷  Free Forever Trial 2034-07-03
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2034-07-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2034-07-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2034-07-03
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Free Forever Trial 2034-07-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
McKesson
Johnson and Johnson
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.